前列腺素D2
前列腺素
医学
免疫系统
前列腺素
受体
过敏性炎症
过敏
免疫学
哮喘
促炎细胞因子
炎症
药理学
内科学
作者
Giancarlo Marone,Maria Rosaria Galdiero,Antonio Pecoraro,Valentina Pucino,Gjada Criscuolo,Maria Triassi,Gilda Varricchi
标识
DOI:10.1080/13543784.2019.1555237
摘要
Introduction: Prostaglandin D2 (PGD2) is a major cyclooxygenase mediator that is synthesized by activated human mast cells and other immune cells. The biological effects of PGD2 are mediated by D-prostanoid (DP1), DP2 (CRTH2) and thromboxane prostanoid (TP) receptors that are expressed on several immune and non-immune cells involved in allergic inflammation. PGD2 exerts various proinflammatory effects relevant to the pathophysiology of allergic disorders. Several selective, orally active, DP2 receptor antagonists and a small number of DP1 receptor antagonists are being developed for the treatment of allergic disorders.Areas covered: The role of DP2 and DP1 receptor antagonists in the treatment of asthma and allergic rhinitis.Expert opinion: Head-to-head studies that compare DP1 antagonists with the standard treatment for allergic rhinitis are necessary to verify the role of these novel drugs as mono- or combination therapies. Further clinical trials are necessary to verify whether DP2 antagonists as monotherapies or, more likely, as add-on therapies, will be effective for the treatment of different phenotypes of adult and childhood asthma. Long-term studies are necessary to evaluate the safety of targeted anti-PGD2 treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI